Multiple pharmacotherapeutic approaches have been approved by the US Food and Drug Administration for the management of overweight and obesity, including orlistat, a gastric and intestinal lipase inhibitor; liraglutide, semaglutide and tirzepatide; GLP-1 receptor agonists; bupropion/naltrexone or phentermine/topiramate combination [64]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.